Analysis of p540+ tetramer binding to circulating CD8+ T cells in HLA-A2- cancer patients and in healthy subjects
. | HLA-A2- cancer patients . | . | . | . | HLA-A2+ healthy subjects . | . | . | . | . | . | HLA-A2- healthy subjects . | . | . | . | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | No. 28 . | No. 29 . | No. 30 . | No. 31 . | No. 1 . | No. 2 . | No. 3 . | No. 4 . | No. 5 . | No. 6 . | No. 1 . | No. 2 . | No. 3 . | No. 4 . | |||||||||||
| Tetramer-positive CD8+ T cells, % | 0.02 | 0.01 | 0.01 | 0.02 | 0.04 | 0.03 | 0.01 | 0 | 0.01 | 0 | 0.01 | 0 | 0.02 | 0 | |||||||||||
. | HLA-A2- cancer patients . | . | . | . | HLA-A2+ healthy subjects . | . | . | . | . | . | HLA-A2- healthy subjects . | . | . | . | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | No. 28 . | No. 29 . | No. 30 . | No. 31 . | No. 1 . | No. 2 . | No. 3 . | No. 4 . | No. 5 . | No. 6 . | No. 1 . | No. 2 . | No. 3 . | No. 4 . | |||||||||||
| Tetramer-positive CD8+ T cells, % | 0.02 | 0.01 | 0.01 | 0.02 | 0.04 | 0.03 | 0.01 | 0 | 0.01 | 0 | 0.01 | 0 | 0.02 | 0 | |||||||||||